In the latest trading session, 0.41 million Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) shares changed hands as the company’s beta touched 0.31. With the company’s most recent per share price at $0.48 changed hands at -$0.09 or -15.72% at last look, the market valuation stands at $5.95M. CMMB’s current price is a discount, trading about -1014.58% off its 52-week high of $5.35. The share price had its 52-week low at $0.50, which suggests the last value was -4.17% down since then. When we look at Chemomab Therapeutics Ltd ADR’s average trading volume, we note the 10-day average is 8.03 million shares, with the 3-month average coming to 1.25 million.
Analysts gave the Chemomab Therapeutics Ltd ADR (CMMB) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended CMMB as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Chemomab Therapeutics Ltd ADR’s EPS for the current quarter is expected to be -$0.02.
Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) trade information
Instantly CMMB was in red as seen in intraday trades today. With action -12.78%, the performance over the past five days has been red. The drop to weekly highs of 1.0800 on Friday, 11/17/23 subtracted -15.72% to the stock’s daily price. The company’s shares are showing year-to-date downside of -85.01%, with the 5-day performance at -12.78% in the red. However, in the 30-day time frame, Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) is -42.20% down. Looking at the short shares, we see there were 32159.999999999996 shares sold at short interest cover period of 1.43 days.
The consensus price target for the stock as assigned by Wall Street analysts is $7.00, meaning bulls need an upside of 93.14% from its recent market value. According to analyst projections, CMMB’s forecast low is $7.00 with $7.00 as the target high. To hit the forecast high, the stock’s price needs a -1358.33% plunge from its current level, while the stock would need to soar -1358.33% for it to hit the projected low.
Chemomab Therapeutics Ltd ADR (CMMB) estimates and forecasts
Data shows that the Chemomab Therapeutics Ltd ADR share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -73.20% over the past 6 months, a 9.09% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Chemomab Therapeutics Ltd ADR will rise 33.30%, while the growth in revenue is estimated to hit 50.00% for the next quarter.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 25.95%. The 2023 estimates are for Chemomab Therapeutics Ltd ADR earnings to decrease by -12.50%.
Chemomab Therapeutics Ltd ADR is expected to release its next quarterly earnings report on November 09.
Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 19.98% of Chemomab Therapeutics Ltd ADR shares while 30.83% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 38.53%. There are 30.83% institutions holding the Chemomab Therapeutics Ltd ADR stock share, with Ikarian Capital, LLC the top institutional holder. As of Jun 29, 2023, the company held 11.60% of the shares, roughly 0.21 million CMMB shares worth $0.28 million.
Kestra Private Wealth Services, LLC holds the second largest percentage of outstanding shares, with 1.70% or 31241.0 shares worth $41081.0 as of Jun 29, 2023.
With 11737.0 shares estimated at $18427.0 under it, the former controlled 0.64% of total outstanding shares.